Our SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.
C2i Genomics was formally founded in 2019 and is based on technology developed at Cornell and the New York Genome Center. We are backed by top tier VCs.
Our Company is headquartered in the US with a CLIA lab in Cambridge, MA, and an R&D center in Israel. We have brought together outstanding professionals with multidisciplinary expertise in oncology, signal processing, bioinformatics and machine learning.
Our C2i Genomics headquarters is located in the thriving life science industry of NYC, in the modern and collaborative workspace at NYU BioLabs.
Our advanced R&D Center is located in Israel’s high-tech city of Haifa among top technology and life science companies.
Our state-of-the-art CLIA certified lab is located in Cambridge, MA, surrounded by innovation and other leading research facilities.
Our team brings together decades of experience across pharmaceutical and diagnostic research and commercialization, military intelligence and healthcare technology to revolutionize cancer monitoring.